Xilio Therapeutics (XLO) Assets Average (2021 - 2026)

Xilio Therapeutics (XLO) has 6 years of Assets Average data on file, last reported at $159.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 82.03% year-over-year to $159.1 million; the trailing twelve-month figure through Mar 2026 stood at $159.1 million (up 82.03% YoY), and the FY2025 full-year result was $112.9 million, up 71.03% from the prior year.
• Assets Average advanced to $159.1 million in Q1 2026, from $144.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $207.2 million in Q1 2022 to a low of $69.4 million in Q4 2023.
• A 5-year average of $120.5 million and a median of $118.8 million in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average sank 53.21% in 2023 and soared 97.88% in 2025, its largest moves.
• Tracing XLO's Assets Average over 5 years: stood at $148.3 million in 2022, then slumped by 53.21% to $69.4 million in 2023, then advanced by 5.02% to $72.9 million in 2024, then soared by 97.88% to $144.2 million in 2025, then grew by 10.33% to $159.1 million in 2026.
• Business Quant data shows XLO's Assets Average at $159.1 million in Q1 2026, $144.2 million in Q4 2025, and $133.8 million in Q3 2025.